Coronary and valvular syndromes and antiphospholipid antibodies.
Since the recognition of the antiphospholipid syndrome (APS), a large number of cardiac manifestations have been reported in association with these antibodies, including coronary artery and valvular disease, cardiomyopathy, and intracardiac thrombosis. Most of these manifestations are explicable on the basis of thrombotic lesions either in the coronary circulation or on the valves and may mimic other similar conditions, such as rheumatic fever or infectious endocarditis. The APS coagulopathy in these patients requires the careful and judicious use of appropriate antiaggregant and anticoagulant therapy. In this review article, the focus will be on the main cardiac features related to the presence of antiphospholipid antibodies (aPLs), which may be of interest to clinicians.
Cervera
Ricard
R
Department of Autoimmune Diseases, Hospital Clínic, Villarroel, 170, 08036 Barcelona, Catalonia, Spain. rcervera@clinic.ub.es
D000328:Adult; D017152:Antibodies, Antiphospholipid / Q000276:immunology* / Q000378:metabolism*; D001011:Aorta / Q000473:pathology; D009202:Cardiomyopathies / Q000276:immunology; D004696:Endocarditis / Q000276:immunology; D005260:Female; D006331:Heart Diseases / Q000276:immunology* / Q000378:metabolism; D006349:Heart Valve Diseases / Q000276:immunology* / Q000378:metabolism; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000276:immunology; D012307:Risk Factors; D013927:Thrombosis / Q000276:immunology
D017152:Antibodies, Antiphospholipid